Whalen Wealth Management »

Halozyme Therapeutics shares owned by Whalen Wealth Management

Quarter-by-quarter ownership of Halozyme Therapeutics (HALO) shares owned by Whalen Wealth Management from 13F filings

Historical chart of Whalen Wealth Management investment in Halozyme Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Halozyme Therapeutics held by Whalen Wealth Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Halozyme Therapeutics by Whalen Wealth Management

Quarter filed Position value Share count Share price at filing
2026-03-31 $419k 6.5k 64.63

More positions owned by Whalen Wealth Management

Ishares Tr Trust Ishare 0-1 (SHV)
NVIDIA Corporation (NVDA)
Ishares Tr 3 7 Yr Treas Bd (IEI)
Apple (AAPL)
Amazon (AMZN)
J P Morgan Exchange Traded F Equity Premium (JEPI)
Goldman Sachs Etf Tr S&p 500 Premium (GPIX)
Microsoft Corporation (MSFT)
Ishares Tr Ibonds Dec 2031 (IBTL)
Meta Platforms Cl A (META)
Ishares Tr Ibonds Dec 29 (IBDU)
Janus Detroit Str Tr Hendrson Aaa Cl (JAAA)
Broadcom (AVGO)
Alphabet Cap Stk Cl A (GOOGL)
Ishares Tr Mbs Etf (MBB)

View all positions for Whalen Wealth Management

Top funds holding Halozyme Therapeutics

BlackRock
Vanguard Group
State Street Corporation
Invesco
Arrowstreet Capital, Limited Partnership
Geode Capital Management
Snyder Capital Management
Dimensional Fund Advisors
Norges Bank Investment Management
William Blair Investment Management
Alliancebernstein
D. E. Shaw & Co
Federated Investors
Jupiter Asset Management
Millennium Management

View all funds holding Halozyme Therapeutics